share_log

EF Hutton Reiterates Buy on Pasithea Therapeutics, Maintains $2 Price Target

Benzinga ·  Jul 10, 2023 12:15

EF Hutton analyst Elemer Piros reiterates Pasithea Therapeutics (NASDAQ:KTTA) with a Buy and maintains $2 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment